DISCOVER

Our News

9 april 2024 - World-first trial could change standard of care for unmethylated glioblastoma patients.

5 march 2024 - Results demonstrate safety and potential efficacy of SonoCloud-9® in treating recurrent glioblastoma.

February 5, 2024 - Registrational study aims to enroll 560 US and EU patients over next two years, with view to obtaining marketing authorization.

December 11, 2023 - Carthera announces an additional €4.5M in funding to complement its Series B financing round, bringing the total raised to €42M ($45M).

November 6, 2023 - Carthera announces the signing of a strategic collaboration with Accord Healthcare Limited, a leading pharmaceutical company, for the supply of carboplatin.

September 18, 2023 – Medical device industry executive with 30+ years expertise brings wealth of experience in product development and commercial launches to support Carthera’s future growth.

June 27, 2023 - New funds will help launch pivotal multicenter trial in patients with recurrent glioblastoma and advance clinical pipeline.

May 3, 2023 - Four-to six-fold increase in drug concentrations measured in human brain after blood-brain barrier opening with SonoCloud-9 System

March 13, 2023 - Carthera and FDA aligned on key aspects of proposed pivotal trial design.

June 22, 2022 - Breakthrough Status allows for enhanced interaction with FDA and recognizes SonoCloud® as innovative and promising approach for treatment of recurrent glioblastoma.